View Financial HealthOncology Pharma 배당 및 자사주 매입배당 기준 점검 0/6Oncology Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 12Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination TherapyOncology Pharma Inc. announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization. On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.공시 • Mar 06Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling StudiesOncology Pharma Inc. announced the initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals. Oncology Pharma will be providing the initial funds to develop and evaluate a dactinomycin nanoemulsion drug product. A version of this product originally received FDA Orphan Drug Designation in 2015. Oncology Pharma has secured access to a broad range of proprietary intellectual property with the potential to make novel drug products to treat cancer that are both safer and more effective than the original drug(s) currently in the market. Oncology Pharma has initiated discussions with NanoSmart on near-term goals including analytical method validation and drug product characterization. Once complete, formal preclinical safety and veterinary clinical studies will be pursued. Veterinary drug development will serve a current and growing need for better treatment options. Data from this project may also be applied towards future regulatory approval to initial human clinical studies for the same drug formulation.공시 • Feb 27Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory AgentOncology Pharma Inc. announced that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent. The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand. The concept of this invention is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.Oncology Pharma is excited about expanding its portfolio in oncology and therapeutics. The company sees a synergy within the portfolio and is continuously building within its expertise while utilizing its Board and Scientific Advisory Board to seek out opportunities to enhance its position within the field of oncology.공시 • Feb 23Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary OncologyOncology Pharma, Inc. announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market. Nanosmart possesses proprietary technology and intellectual property rights for the development of liposomal and/or emulsion-based drug formulations that incorporate anti-nuclear antibodies (ANA). ANA may be utilized as a targeting agent in pharmaceutical compounds to deliver active pharmaceutical ingredients to tumor sites, potentially resulting in safer and more effective cancer therapies. ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market.공시 • Feb 18Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory BoardOncology Pharma Inc. announced that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA tests for detecting cancer. In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England.공시 • Feb 10Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials PlatformOncology Pharma Inc. announced that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including drug development, clinical trials, personalized oncology and therapeutics. Connect2Med provides a motivating trial experience through increased engagement and easy to use communication tools. They have access to a dedicated trial specific portal (patient facing app), where they can perform functions like eDiary, ePRO, telehealth visits. The platform is FHIR compatible and easily integrates with EHR, CTMS, CRM from major vendors in the industry. Patients’ workflow can be automated through a set of digital workflows, with automated interventions and escalation when needed. Sites and CROs can post upcoming trials in a public space for all to see, boosting public awareness through social sharing. Site owners and Sponsors have access to impactful data, metrics and reports that allow them to make strategic decisions to improve retention, growth, performance, satisfaction and ROI.공시 • Jan 29Oncology Pharma Announces the Appointment of James Smith as New Chief Financial OfficerOncology Pharma Inc. that it has retained the services of Mr. James Smith, CPA as its new Chief Financial Officer. Mr. James Smith, CPA is a seasoned executive officer with experience encompassing multiple public and private companies across a variety of industries. His prior experience includes CEO and/or CFO in two fully reporting SEC registrants as well as numerous OTC Pink Sheet companies in either the CFO, outside accountant or CEO capacities. In addition, during his employment with two national accounting firms and in his own CPA firm practice, Mr. Smith has worked with multiple Family Offices and investors in assisting them with their operations, capital placement, organizational strategy and structure, with an emphasis on tax and estate planning. Oncology Pharma is pleased to welcome Mr. Smith aboard as the Company is working towards expanding its portfolio and financing.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ONPH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ONPH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Oncology Pharma 배당 수익률 vs 시장ONPH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ONPH)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.4%분석가 예측 (ONPH) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ONPH 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ONPH 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ONPH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ONPH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:25종가2026/05/21 00:00수익2013/03/31연간 수익2013/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Oncology Pharma Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 12Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination TherapyOncology Pharma Inc. announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization. On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.
공시 • Mar 06Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling StudiesOncology Pharma Inc. announced the initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals. Oncology Pharma will be providing the initial funds to develop and evaluate a dactinomycin nanoemulsion drug product. A version of this product originally received FDA Orphan Drug Designation in 2015. Oncology Pharma has secured access to a broad range of proprietary intellectual property with the potential to make novel drug products to treat cancer that are both safer and more effective than the original drug(s) currently in the market. Oncology Pharma has initiated discussions with NanoSmart on near-term goals including analytical method validation and drug product characterization. Once complete, formal preclinical safety and veterinary clinical studies will be pursued. Veterinary drug development will serve a current and growing need for better treatment options. Data from this project may also be applied towards future regulatory approval to initial human clinical studies for the same drug formulation.
공시 • Feb 27Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory AgentOncology Pharma Inc. announced that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent. The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand. The concept of this invention is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.Oncology Pharma is excited about expanding its portfolio in oncology and therapeutics. The company sees a synergy within the portfolio and is continuously building within its expertise while utilizing its Board and Scientific Advisory Board to seek out opportunities to enhance its position within the field of oncology.
공시 • Feb 23Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary OncologyOncology Pharma, Inc. announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market. Nanosmart possesses proprietary technology and intellectual property rights for the development of liposomal and/or emulsion-based drug formulations that incorporate anti-nuclear antibodies (ANA). ANA may be utilized as a targeting agent in pharmaceutical compounds to deliver active pharmaceutical ingredients to tumor sites, potentially resulting in safer and more effective cancer therapies. ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market.
공시 • Feb 18Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory BoardOncology Pharma Inc. announced that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA tests for detecting cancer. In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England.
공시 • Feb 10Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials PlatformOncology Pharma Inc. announced that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including drug development, clinical trials, personalized oncology and therapeutics. Connect2Med provides a motivating trial experience through increased engagement and easy to use communication tools. They have access to a dedicated trial specific portal (patient facing app), where they can perform functions like eDiary, ePRO, telehealth visits. The platform is FHIR compatible and easily integrates with EHR, CTMS, CRM from major vendors in the industry. Patients’ workflow can be automated through a set of digital workflows, with automated interventions and escalation when needed. Sites and CROs can post upcoming trials in a public space for all to see, boosting public awareness through social sharing. Site owners and Sponsors have access to impactful data, metrics and reports that allow them to make strategic decisions to improve retention, growth, performance, satisfaction and ROI.
공시 • Jan 29Oncology Pharma Announces the Appointment of James Smith as New Chief Financial OfficerOncology Pharma Inc. that it has retained the services of Mr. James Smith, CPA as its new Chief Financial Officer. Mr. James Smith, CPA is a seasoned executive officer with experience encompassing multiple public and private companies across a variety of industries. His prior experience includes CEO and/or CFO in two fully reporting SEC registrants as well as numerous OTC Pink Sheet companies in either the CFO, outside accountant or CEO capacities. In addition, during his employment with two national accounting firms and in his own CPA firm practice, Mr. Smith has worked with multiple Family Offices and investors in assisting them with their operations, capital placement, organizational strategy and structure, with an emphasis on tax and estate planning. Oncology Pharma is pleased to welcome Mr. Smith aboard as the Company is working towards expanding its portfolio and financing.